| Not Yet Recruiting | A Single-arm, Open-label, Multicenter, Phase Ib/II Clinical Trial of CVL237 Tablets in Combination With Serplu NCT07446049 | Convalife (Shanghai) Co., Ltd. | Phase 2 |
| Not Yet Recruiting | BC3195 in Combination With Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors NCT07469774 | Biocity Biopharmaceutics Co., Ltd. | Phase 1 / Phase 2 |
| Not Yet Recruiting | Phase 2 Clinical Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of GH21 Capsules C NCT07318649 | Suzhou Genhouse Bio Co., Ltd. | Phase 2 |
| Recruiting | A Study of YL202 in Patients With Advanced Solid Tumors NCT07202364 | MediLink Therapeutics (Suzhou) Co., Ltd. | Phase 2 |
| Recruiting | A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors NCT07066657 | ArriVent BioPharma, Inc. | Phase 1 |
| Recruiting | Study of IBI3005 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors NCT06418061 | Innovent Biologics (Suzhou) Co. Ltd. | Phase 1 |
| Active Not Recruiting | A Study to Evaluate the Safety, Tolerability, PK, PD, and Preliminary Efficacy of CS01 in Patients With Locall NCT07461181 | Ruijin Hospital | Phase 1 / Phase 2 |
| Recruiting | Study of XB010 in Subjects With Solid Tumors NCT06545331 | Exelixis | Phase 1 |
| Recruiting | A Study to Investigate ANS014004 in Participants With Locally Advanced or Metastatic Solid Tumors NCT06307795 | Avistone Biotechnology Co., Ltd. | Phase 1 |
| Active Not Recruiting | A Study to Evaluate ANS014004 in Subjects With Locally Advanced or Metastatic Solid Tumors NCT06328439 | Avistone Biotechnology Co., Ltd. | Phase 1 |
| Recruiting | A Study of BL-M05D1 in Patients With Locally Advanced or Metastatic Solid Tumors NCT06349811 | Sichuan Baili Pharmaceutical Co., Ltd. | Phase 1 |
| Recruiting | Clinical Trial to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of DA-450 NCT06293651 | Dong-A ST Co., Ltd. | Phase 1 / Phase 2 |
| Recruiting | PTT-936 Alone or in Combination in Patients With Locally Advanced or Metastatic Solid Tumors NCT06244992 | Pyrotech Therapeutics, Inc. | Phase 1 / Phase 2 |
| Recruiting | A Study of TYK-00540 in Adult Patients With Solid Tumors NCT06246071 | TYK Medicines, Inc | Phase 1 |
| Recruiting | A Study of YL202 in Selected Patients With Advanced Solid Tumors NCT06107686 | MediLink Therapeutics (Suzhou) Co., Ltd. | Phase 2 |
| Unknown | Clinical Study of SM3321 With Solid Tumors NCT06087770 | Beijing StarMab Biomed Technology Ltd | Phase 1 |
| Recruiting | A Study to Investigate the Safety, Pharmacokinetics, and Clinical Activity of AP203 in Patients with Locally A NCT05473156 | AP Biosciences Inc. | Phase 1 / Phase 2 |
| Unknown | Study of BC3195 Monotherapy in Patients With Advanced Solid Tumors NCT05957471 | Biocity Biopharmaceutics Co., Ltd. | Phase 1 |
| Recruiting | IFNα Expressing Mesenchymal Stromal Cells for Locally Advanced/Metastatic Solid Tumors NCT05699811 | Chinese PLA General Hospital | Phase 1 / Phase 2 |
| Recruiting | A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combinat NCT05581004 | Genentech, Inc. | Phase 1 |
| Recruiting | A Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of ATG 037 Monother NCT05205109 | Antengene Therapeutics Limited | Phase 1 |
| Unknown | HLX35(EGFR×4-1BB Bispecific) in Patients With Advanced or Metastatic Solid Tumors NCT05360381 | Shanghai Henlius Biotech | Phase 1 |
| Unknown | HLX301 (TIGIT×PDL1 Bispecific) in Patients With Locally Advanced or Metastatic Solid Tumors NCT05102214 | Shanghai Henlius Biotech | Phase 1 / Phase 2 |
| Completed | IN10018 Combination Therapy in Previously-treated Locally Advanced or Metastatic Solid Tumor Patients NCT05830539 | InxMed (Shanghai) Co., Ltd. | Phase 1 / Phase 2 |
| Recruiting | A Study of XZP-5955 Tablets in Patients With NTRK or ROS1 Fusion Positive Locally Advanced or Metastatic Solid NCT04996121 | Xuanzhu Biopharmaceutical Co., Ltd. | Phase 1 / Phase 2 |
| Unknown | Study of Anti-5T4 CAR-raNK Cell Therapy in Locally Advanced or Metastatic Solid Tumors NCT05137275 | Shanghai East Hospital | EARLY_Phase 1 |
| Completed | Assessment of Safety and Preliminary Clinical Efficacy with BAT6005 in Advanced Malignant Solid Tumors NCT05116709 | Bio-Thera Solutions | Phase 1 |
| Terminated | A Dose-escalation Study of LUNA18 in Patients With Locally Advanced or Metastatic Solid Tumors (With Expansion NCT05012618 | Chugai Pharmaceutical | Phase 1 |
| Active Not Recruiting | A Dose-Escalation Study of SPYK04 in Patients With Locally Advanced or Metastatic Solid Tumors (With Expansion NCT04511845 | Chugai Pharmaceutical | Phase 1 |
| Terminated | First-In-Human (FIH) Study of W0180 as Single Agent and in Combination With Pembrolizumab in Adults With Local NCT04564417 | Pierre Fabre Medicament | Phase 1 |
| Unknown | Study of AMV564 in Subjects With Advanced Solid Tumors NCT04128423 | Amphivena Therapeutics, Inc. | Phase 1 |
| Completed | Study of CS3006 in Subjects With Locally Advanced or Metastatic Solid Tumors NCT03736850 | CStone Pharmaceuticals | Phase 1 |
| Terminated | Javelin BRCA/ATM: Avelumab Plus Talazoparib in Patients With BRCA or ATM Mutant Solid Tumors NCT03565991 | Pfizer | Phase 2 |
| Completed | Study to Evaluate Safety and Tolerability of GX-I7 in Patients With Locally Advanced or Metastatic Solid Tumor NCT03478995 | Genexine, Inc. | Phase 1 |
| Completed | Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) i NCT03150810 | BeiGene | Phase 1 |
| Active Not Recruiting | MPDL3280A-treatment-IST-UMCG NCT02478099 | University Medical Center Groningen | Phase 2 |
| Completed | A Phase 1b Study of Demcizumab Plus Pembrolizumab in Locally Advanced or Metastatic Solid Tumors NCT02722954 | OncoMed Pharmaceuticals, Inc. | Phase 1 |
| Completed | Oral Bioavailability and Mass Balance Trial With Pimasertib NCT01713036 | Merck KGaA, Darmstadt, Germany | Phase 1 |
| Completed | A Combination Therapy Study of MK-2206 and AZD6244 in Participants With Advanced Solid Tumors (MK-2206-010) NCT01021748 | Merck Sharp & Dohme LLC | Phase 1 |